Compare Citius Pharmaceuticals Inc (CTXR) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Remitly Global Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Remitly Global Inc trades at $23.5 (market cap $4.98B). The key difference: Remitly Global Inc is far larger — about 365.6× Citius Pharmaceuticals Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Remitly Global Inc for 53 Days on average.
| CTXR | RELY | |
|---|---|---|
Market Cap | $13.62M | $4.98B |
Volume | 132,438 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $1.82 | $26.92 |
52-Week Low | $0.48 | $12.20 |
Typical Hold Time | 16 Days | 53 Days |
Enterprise Value | $3.79M | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. Revenue has grown from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. The company recently announced a partnership with Etsy and reported Q2 2026 revenue growth of 20% to $495M, with active customers surpassing 10 million.
The outlook is positive, supported by robust earnings beats, expanding margins, and a consensus analyst price target of $30.50 implying significant upside. Key risks include reliance on continued customer growth, competitive pressures in digital payments, and market volatility. Institutional ownership trends and insider sales warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
